OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143. (Q53928519)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143. |
scientific article |
Statements
OS10.3 of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143 (English)
D. A. Reardon
A. Omuro
A. A. Brandes
J. Rieger
A. Wick
J. Sepulveda
S. Phuphanich
P. de Souza
M. S. Ahluwalia
G. Vlahovic
19 April 2017
1 reference